Arrowhead Pharmaceuticals Inc. and Vivo Capital LLC have launched a joint venture named Visirna Therapeutics for RNA interference therapeutics in the greater China market. Arrowhead is the majority shareholder of the new entity, while Vivo invested $60 million in the new entity.
Chimera Bioengineering Inc. has been selected as the winner of the Asian Fund for Cancer Research's (AFCR) 2021 BRACE Award Venture Competition, contributing $500,000 as part of a recent $7.5 million capital infusion and bringing to $26 million the company’s total amount raised to date.
Aurion Biotech Inc. pulled down a $120 million financing to advance efforts with its lead candidate, a cell therapy for the treatment of corneal edema secondary to endothelial dysfunction (CESED).
After securing $70 million in series B funding, Chinese biotech Medilink Therapeutics Co. Ltd. is gearing up to enter the clinic with its next-generation antibody-drug conjugates (ADCs).
A new study from researchers at Aevisbio Inc. and the National Institutes of Health on the effect of 3,6’-dithiopomalidomide on neuroinflammation adds new detail to what might one day become a significant new therapeutic strategy to treat Alzheimer's disease and other neurological disorders.
PERTH, Australia – Prota Therapeutics Ltd.’s lead candidate PRT-120 induced clinical remission of peanut allergy in 51% of children in a phase IIb clinical trial. There are currently no curative therapies to treat food allergies, Prota Therapeutics CEO Mimi Tang told BioWorld. Peanut allergy in children can be particularly problematic because the only treatment is avoidance.
PERTH, Australia – After raising AU$7.5 million (US$5.4 million) in a private placement, biopharma company Servatus Ltd. is advancing its microbial biotherapeutics clinical programs targeting serious autoimmune conditions. The Coolum, Queensland-based private company is focused on identifying and developing live microbial biotherapeutics and engineered proteins to treat chronic and autoimmune diseases, as well as non-antibiotic treatments for bacterial infections.
Binhui Biopharmaceutical Co. Ltd.’s BS-001, a recombinant human oncolytic herpes simplex virus type-2 expressing GM-CSF for the potential treatment of solid tumors, has gained an IND approval from the FDA.
With a special interest in neurological disorders, Hopstem Biotechnology Co. Ltd. closed a series A++ round to raise nearly ¥100 million (US$15.5 million) to advance hNPC-01, an off-the-shelf induced pluripotent stem cells (iPSC)-derived human forebrain neural progenitor cell product to treat chronic conditions caused by stroke and traumatic brain injuries.
PERTH, Australia – Suda Pharmaceuticals Ltd. saw its stock shoot up nearly 44% on the heels of an oversubscribed AU$3.65 million (US$2.71 million) capital raise after acquiring a new invariant natural killer T (iNKT) cell therapy platform for oncology.
RSS
